Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL RHABDOMYOSARCOMA DRUG INDUSTRY
2.1 Summary about Rhabdomyosarcoma Drug Industry
2.2 Rhabdomyosarcoma Drug Market Trends
2.2.1 Rhabdomyosarcoma Drug Production & Consumption Trends
2.2.2 Rhabdomyosarcoma Drug Demand Structure Trends
2.3 Rhabdomyosarcoma Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 ARI-4175
4.2.2 Celyvir
4.2.3 Crizotinib
4.2.4 Enoblituzumab
4.2.5 AT-69
4.2.6 Axitinib
4.2.7 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Research Center
4.3.2 Hospital
4.3.3 Clinic
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 ARI-4175
5.2.2 Celyvir
5.2.3 Crizotinib
5.2.4 Enoblituzumab
5.2.5 AT-69
5.2.6 Axitinib
5.2.7 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Research Center
5.3.2 Hospital
5.3.3 Clinic
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 ARI-4175
6.2.2 Celyvir
6.2.3 Crizotinib
6.2.4 Enoblituzumab
6.2.5 AT-69
6.2.6 Axitinib
6.2.7 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Research Center
6.3.2 Hospital
6.3.3 Clinic
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 ARI-4175
7.2.2 Celyvir
7.2.3 Crizotinib
7.2.4 Enoblituzumab
7.2.5 AT-69
7.2.6 Axitinib
7.2.7 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Research Center
7.3.2 Hospital
7.3.3 Clinic
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 ARI-4175
8.2.2 Celyvir
8.2.3 Crizotinib
8.2.4 Enoblituzumab
8.2.5 AT-69
8.2.6 Axitinib
8.2.7 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Research Center
8.3.2 Hospital
8.3.3 Clinic
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 ARI-4175
9.2.2 Celyvir
9.2.3 Crizotinib
9.2.4 Enoblituzumab
9.2.5 AT-69
9.2.6 Axitinib
9.2.7 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Research Center
9.3.2 Hospital
9.3.3 Clinic
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Bellicum Pharmaceuticals Inc
10.1.2 Boehringer Ingelheim GmbH
10.1.3 Bristol-Myers Squibb Co
10.1.4 Celgene Corp
10.1.5 Eisai Co Ltd
10.1.6 Epizyme Inc
10.1.7 Exelixis Inc
10.1.8 Iproteos SL
10.1.9 Ipsen SA
10.1.10 MacroGenics Inc
10.1.11 NantKwest Inc
10.1.12 Novartis AG
10.1.13 Noxxon Pharma AG
10.1.14 Pfizer Inc
10.1.15 Taiho Pharmaceutical Co Ltd
10.1.16 Taiwan Liposome Company Ltd
10.1.17 Tarveda Therapeutics Inc
10.2 Rhabdomyosarcoma Drug Sales Date of Major Players (2017-2020e)
10.2.1 Bellicum Pharmaceuticals Inc
10.2.2 Boehringer Ingelheim GmbH
10.2.3 Bristol-Myers Squibb Co
10.2.4 Celgene Corp
10.2.5 Eisai Co Ltd
10.2.6 Epizyme Inc
10.2.7 Exelixis Inc
10.2.8 Iproteos SL
10.2.9 Ipsen SA
10.2.10 MacroGenics Inc
10.2.11 NantKwest Inc
10.2.12 Novartis AG
10.2.13 Noxxon Pharma AG
10.2.14 Pfizer Inc
10.2.15 Taiho Pharmaceutical Co Ltd
10.2.16 Taiwan Liposome Company Ltd
10.2.17 Tarveda Therapeutics Inc
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
